Dapagliflozin a Glucose-Regulating Drug with Diuretic Properties T2D

Dapagliflozin-induced SGLT2 inhibition for 12 weeks is associated with reductions in 24-hour BP, body weight, GFR, and possibly plasma volume. Cumulatively, these effects suggest that dapagliflozin may have a diuretic-like capacity to lower BP in addition to beneficial effects on glycemic control (Diabetes, Obesity and Metabolism)